# Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

> **NCT00427414** · PHASE1 · TERMINATED · sponsor: **AIDS Malignancy Consortium** · enrollment: 14 (actual)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** liposomal daunorubicin citrate

## Key facts

- **NCT ID:** NCT00427414
- **Lead sponsor:** AIDS Malignancy Consortium
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2010-11
- **Final completion:** 2011-11
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2015-04-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00427414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00427414, "Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00427414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*